Update

U.K. Economy Grew 0.7% in Third Quarter, Matching Median Forecast
Tweet TWEET

Ablynx: Publication in Accordance With Articles 14 and 15 of the Belgian Law of 2 May 2007 on the Publication of Major

Ablynx: Publication in Accordance With Articles 14 and 15 of the Belgian Law of 
2 May 2007 on the Publication of Major Shareholdings
(the "Transparency Law") 
REGULATED INFORMATION 
GHENT, BELGIUM -- (Marketwire) -- 03/08/13 --  Ablynx (EURONEXT
BRUSSELS: ABLX), the biopharmaceutical company focused on the
discovery and development of Nanobodies(R), announces today that the
closing of its private placement ("Accelerated Bookbuild
Offering"/"ABO") took place on 5 March 2013 and as a result, Ablynx
issued 4,377,919 new shares. In addition, 348,400 new shares were
issued that same day as a result of the exercise of 641,800 warrants. 
Ablynx NV also publishes the following information in accordance with
article 15 of the Law of 2 May 2007 on the publication of major
shareholdings in issuers whose shares are admitted to trading on a
regulated market (the "Transparency Law"): 


 
-----------------------------------------------------------------
----
Total amount of the share capital:                  EUR 90,653,858.30
---------------------------------------------------------------------
Total number of securities carrying voting rights:  48,505,516       
---------------------------------------------------------------------
Total number of voting rights (denominator):        48,505,516       
---------------------------------------------------------------------

 
Ablynx NV has in total 3,904,145 outstanding warrants, of which
1,657,700 warrants give the holder the right to a total of 828,850
shares (two warrants giving the right to subscribe to one share) and
of which 2,246,445 warrants give the holder the right to a total of
2,246,445 shares (one warrant giving the right to subscribe to one
share). The acceptance and issuing of 467,500 warrants (one warrant
giving the right to subscribe to one share) is pending. The total
number of voting rights, which can be acquired as a result of the
exercise of the outstanding warrants, amounts to 3,075,295. 
In addition, Ablynx NV announces, in accordance with article 14 of
the Law of 2 May 2007 on the publication of major shareholdings in
issuers whose shares are admitted to trading on a regulated market
(the "Transparency Law"), that it has received the following
transparency notifications between 28 February and 7 March 2013.  


 
-----------------------------------------------------------------
-------
Notifier(s)                                Number of      Percentage of 
                                           voting rights  voting rights 
------------------------------------------------------------------------
Gimv NV, Adviesbeheer Gimv Life Sciences      5,825,939       12.01%    
NV, Adviesbeheer Gimv Life Sciences 2004                                
NV and Biotech Fonds Vlaanderen NV(1)                                   
------------------------------------------------------------------------
Sofinnova Partners SAS                       4,675,587         9.63%    
------------------------------------------------------------------------

 
(1) Gimv NV controls Adviesbeheer Gimv Life Sciences NV and
Adviesbeheer Gimv Life Sciences 2004 NV. Gimv NV (2,463,320 voting
rights), Adviesbeheer Gimv Life Sciences NV (0 voting rights),
Adviesbeheer Gimv Life Sciences 2004 NV (433,745 voting rights) and
Biotech Fonds Vlaanderen NV (2,928,874 voting rights) are acting in
mutual agreement. The Flemish Region in Belgium is the ultimate
shareholder of Biotech Fonds Vlaanderen NV. 
The full versions of the transparency notifications are available on
the website of Ablynx (www.ablynx.com - investor relations). 
About Ablynx
 Ablynx is a biopharmaceutical company engaged in the
discovery and development of Nanobodies(R), a novel class of
therapeutic proteins based on single-domain antibody fragments, for a
range of serious human diseases, including inflammation, haematology,
oncology and pulmonary disease. Today, the Company has approximately
25 programmes in the pipeline and five Nanobodies at clinical
development stage. Ablynx has on-going research collaborations and
significant partnerships with major pharmaceutical companies
including Boehringer Ingelheim, Merck Serono, Novartis and Merck &
Co. The Company is headquartered in Ghent, Belgium.  
More information can be found on www.ablynx.com. 
press release in pdf http://hugin.info/137912/R/1684075/551329.pdf  
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / 
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com 
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03 
e: marieke.vermeersch@ablynx.com 
Follow us on Twitter @AblynxABLX 
M:Communications:
Mary-Jane Elliott
Amber Bielecka
Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com 
 
 
Press spacebar to pause and continue. Press esc to stop.